Form 4: Replimune CMO Receives Significant Equity Grants

Replimune Group's Chief Medical Officer, Konstantinos Xynos, was granted 50,000 restricted stock units and 75,000 stock options as part of executive compensation.

Summary

• Konstantinos Xynos, Chief Medical Officer of Replimune Group, Inc., was granted 50,000 Restricted Stock Units (RSUs) on April 1, 2026.
• Xynos also received 75,000 employee stock options with an exercise price of $7.61 per share.
• The RSUs vest over a four-year period, with the first 25% vesting on May 15, 2027, and the remainder in three equal annual installments through 2030.
• The stock options vest over four years, with 25% vesting on April 1, 2027, followed by 36 equal monthly installments.
• Following these transactions, Xynos directly owns 249,685 shares of common stock and 75,000 options.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral-to-positive sign of executive alignment, though the score is slightly tempered by the administrative filing delay.

Positives

• Significant equity grants align the Chief Medical Officer's interests with long-term shareholder value.
• The four-year vesting schedule serves as a strong retention mechanism for key clinical leadership.
• The exercise price of $7.61 establishes a clear baseline for management's expectations of future stock appreciation.

Negatives

• The disclosure was filed late due to an administrative error, which may indicate minor internal reporting lapses.
• The issuance of 125,000 new equity instruments represents potential future dilution for existing shareholders.

Risks

• Executive retention and incentive value are tied to the stock price remaining above the $7.61 exercise price.
• Administrative errors in regulatory filings can occasionally lead to increased scrutiny from oversight bodies.

Future Outlook

The long-term vesting schedule suggests a commitment to maintaining leadership stability within the medical department as the company advances its clinical pipeline through 2030.

Management Comments

• This Form 4 is being filed late due to inadvertent administrative error.

Industry Context

StockSavvy.ai notes that equity-heavy compensation packages are standard in the biotechnology sector to preserve cash reserves while incentivizing executives to reach clinical and regulatory milestones.

Comparison to Industry Standards

• The grant size is consistent with mid-cap biotech executive compensation benchmarks for C-suite roles.
• A four-year vesting period is the standard industry duration for talent retention in the pharmaceutical space.
• The mix of RSUs and options is a common strategy used by peers like Amgen and Gilead to balance immediate retention with performance-based incentives.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential long-term dilution from the eventual conversion of 125,000 equity units.
• Employees: Signals stability and continuity in the company's medical leadership.

Next Steps

• Vesting of the first 25% of stock options on April 1, 2027.
• Vesting of the first 25% of restricted stock units on May 15, 2027.

Key Dates

Recommendation

This is a routine administrative filing regarding executive compensation. While it demonstrates management's continued commitment, it does not provide new material information regarding clinical trials or financial results that would justify a change in investment rating.

Keywords

Replimune Group, REPL, Executive Compensation, Insider Trading, Stock Options, Restricted Stock Units, Konstantinos Xynos, Biotechnology